NASDAQ:APLS Apellis Pharmaceuticals (APLS) Stock Price, News & Analysis $27.34 +0.66 (+2.47%) (As of 10/28/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Apellis Pharmaceuticals Stock (NASDAQ:APLS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get APLS alerts:Sign Up Key Stats Today's Range$26.68▼$27.8050-Day Range$26.67▼$41.0552-Week Range$26.28▼$73.80Volume2.25 million shsAverage Volume1.69 million shsMarket Capitalization$3.32 billionP/E RatioN/ADividend YieldN/APrice Target$65.41Consensus RatingModerate Buy Company OverviewApellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Read More… 24/7 Automated Profits in Crypto (Ad)What if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast world of passive crypto income, where you set up a dependable income stream that works for you, whether you're at your computer or living your life.>> Secure Your Spot On The Groundbreaking Workshop Here Apellis Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks91st Percentile Overall ScoreAPLS MarketRank™: Apellis Pharmaceuticals scored higher than 91% of companies evaluated by MarketBeat, and ranked 124th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingApellis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 12 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageApellis Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Apellis Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Apellis Pharmaceuticals are expected to grow in the coming year, from ($1.37) to $0.01 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Apellis Pharmaceuticals is -9.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Apellis Pharmaceuticals is -9.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApellis Pharmaceuticals has a P/B Ratio of 16.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Apellis Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.38% of the outstanding shares of Apellis Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverApellis Pharmaceuticals has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Apellis Pharmaceuticals has recently increased by 38.20%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldApellis Pharmaceuticals does not currently pay a dividend.Dividend GrowthApellis Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.27 Percentage of Shares Shorted17.38% of the outstanding shares of Apellis Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverApellis Pharmaceuticals has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Apellis Pharmaceuticals has recently increased by 38.20%, indicating that investor sentiment is decreasing significantly. News and Social Media2.4 / 5News Sentiment0.29 News SentimentApellis Pharmaceuticals has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Apellis Pharmaceuticals this week, compared to 8 articles on an average week.Search InterestOnly 14 people have searched for APLS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Apellis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Apellis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,340,510.00 in company stock.Percentage Held by InsidersOnly 6.80% of the stock of Apellis Pharmaceuticals is held by insiders.Percentage Held by Institutions96.29% of the stock of Apellis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Apellis Pharmaceuticals' insider trading history. Receive APLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address APLS Stock News HeadlinesApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Short Interest Up 38.2% in OctoberOctober 29 at 2:58 AM | americanbankingnews.comApellis Pharmaceuticals (NASDAQ:APLS) Coverage Initiated by Analysts at Royal Bank of CanadaOctober 29 at 1:49 AM | americanbankingnews.comTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…October 29, 2024 | Timothy Sykes (Ad)Stifel Nicolaus Sticks to Their Buy Rating for Apellis Pharmaceuticals (APLS)October 28 at 10:30 PM | markets.businessinsider.comApellis Pharmaceuticals (APLS) Gets a Buy from TD CowenOctober 28 at 10:30 PM | markets.businessinsider.comApellis, Sobi announced results from Phase 3 VALIANT studyOctober 27 at 12:12 PM | markets.businessinsider.comApellis Pharmaceuticals (NASDAQ:APLS) PT Lowered to $38.00 at MizuhoOctober 27 at 4:25 AM | americanbankingnews.comPivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGNOctober 26 at 2:00 PM | globenewswire.comSee More Headlines APLS Stock Analysis - Frequently Asked Questions How have APLS shares performed this year? Apellis Pharmaceuticals' stock was trading at $59.86 at the start of the year. Since then, APLS shares have decreased by 54.3% and is now trading at $27.34. View the best growth stocks for 2024 here. How were Apellis Pharmaceuticals' earnings last quarter? Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) posted its quarterly earnings results on Thursday, August, 1st. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.03. The business's revenue was up 110.2% on a year-over-year basis. Does Apellis Pharmaceuticals have any subsidiaries? Apellis Pharmaceuticals subsidiaries include these companies: Potentia Pharmaceuticals, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., and others. When did Apellis Pharmaceuticals IPO? Apellis Pharmaceuticals (APLS) raised $150 million in an initial public offering on Thursday, November 9th 2017. The company issued 10,700,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO. Who are Apellis Pharmaceuticals' major shareholders? Top institutional shareholders of Apellis Pharmaceuticals include Assenagon Asset Management S.A. (1.77%), SG Americas Securities LLC, Sippican Capital Advisors (0.02%) and Handelsbanken Fonder AB (0.02%). Insiders that own company stock include Pascal Deschatelets, Alec Machiels, Cedric Francois, David O Watson, A Sinclair Dunlop, Federico Grossi, Timothy Eugene Sullivan, Adam J Townsend, Jeffrey Eisele, Lukas Scheibler, Nur Nicholson, Mark Jeffrey Delong, Karen Lewis, James George Chopas, Caroline Baumal, Victoria L Brown and Morningside Venture Investment. View institutional ownership trends. How do I buy shares of Apellis Pharmaceuticals? Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Apellis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Apellis Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings8/01/2024Today10/29/2024Next Earnings (Confirmed)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:APLS CUSIPN/A CIK1492422 Webwww.apellis.com Phone(617) 977-5700FaxN/AEmployees702Year Founded2009Price Target and Rating Average Stock Price Target$65.41 High Stock Price Target$106.00 Low Stock Price Target$25.00 Potential Upside/Downside+139.3%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-528,630,000.00 Net Margins-52.99% Pretax Margin-52.63% Return on Equity-138.32% Return on Assets-39.63% Debt Debt-to-Equity Ratio1.73 Current Ratio5.08 Quick Ratio4.18 Sales & Book Value Annual Sales$628.79 million Price / Sales5.28 Cash FlowN/A Price / Cash FlowN/A Book Value$1.64 per share Price / Book16.67Miscellaneous Outstanding Shares121,366,000Free Float113,486,000Market Cap$3.32 billion OptionableOptionable Beta0.87 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (NASDAQ:APLS) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.